August 06, 2010
Michael R. Moore, M.D., F.A.C.P., hematologist / oncologist at the Willis-Knighton Cancer Center, has returned from New Orleans where he presented the results of a phase II study at the Poster Session of the American Society of Hematology Meeting. The study was entitled "Efficacy and Safety of Romiplostim in Patients with Low- or Intermediate-Risk Myelodysplastic Syndtome (MDS) Receiving Decitibine."
Moore was one of eight authors of the study. The others hailed from such prestigious institutions like Stanford University, M.D. Anderson Cancer Center, U.C. San Francisco Medical Center and the Weill Medical College at Cornell University.
Moore is a physician with Hematology/Oncology Associates located in suite 240 of the Willis Knighton Cancer Center at 2600 Kings Highway in Shreveport.